Northwest Biotherapeutics (NWBO) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$16.9 million.
- Northwest Biotherapeutics' Income from Continuing Operations fell 35.54% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 541.68%. This contributed to the annual value of -$74.3 million for FY2024, which is 2226.54% down from last year.
- As of Q3 2025, Northwest Biotherapeutics' Income from Continuing Operations stood at -$16.9 million, which was down 35.54% from -$16.6 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Income from Continuing Operations ranged from a high of -$11.7 million in Q3 2021 and a low of -$22.5 million during Q2 2022
- In the last 5 years, Northwest Biotherapeutics' Income from Continuing Operations had a median value of -$16.9 million in 2024 and averaged -$16.8 million.
- Data for Northwest Biotherapeutics' Income from Continuing Operations shows a peak YoY increase of 7818.48% (in 2021) and a maximum YoY decrease of 14848.66% (in 2021) over the last 5 years.
- Over the past 5 years, Northwest Biotherapeutics' Income from Continuing Operations (Quarter) stood at -$11.8 million in 2021, then crashed by 64.0% to -$19.4 million in 2022, then grew by 15.54% to -$16.4 million in 2023, then decreased by 28.09% to -$21.0 million in 2024, then rose by 19.28% to -$16.9 million in 2025.
- Its Income from Continuing Operations stands at -$16.9 million for Q3 2025, versus -$16.6 million for Q2 2025 and -$18.9 million for Q1 2025.